Specialty Pharmacy

Immunotherapy combination outperforms chemotherapy in patients with advanced or metastatic renal cell carcinoma.

Breast cancer survivors are more likely to die from heart disease than cancer.

Top news of the day from across the health care landscape.

New combination therapy gains approval for adult and pediatric patients with HIV-1.

The risk of non-Hodgkin's lymphoma is elevated in patients with hepatitis C virus.

Direct and indirect remuneration fees remain a top concern for pharmacists in 2018.

Reimbursement changes leave Arkansas pharmacies in jeopardy.

Ron Lanton III, Esq., President, True North Political Solutions, touches on some policies that are changing and may support biosimilar development.

Immunotherapy combination beneficial for patients with lung cancer with a high tumor mutation burden.

HIV may target CD4+ T cells that have a higher prevalence of a certain protein on their surfaces.

Top news of the day from across the health care landscape.

The genetic makeup of influenza may be able to determine how a strain will multiply.

Chronic HCV infection has been linked to low serum zinc and low metallothioneins expression in liver cells.

Thirty-five percent of drug approvals in 2017 were personalized drugs.

With more biosimilars poised to enter the market, stakeholders seek to ensure safety and efficacy.

The RAISE Family Caregivers Act aids individuals taking care of loved ones with chronic diseases.

Cutaneous T-cell lymphoma treatment may increase the risk of death among certain patients.

Top news of the day from across the health care landscape.

Ion channel inhibitors show promise reducing the high cost of conventional hepatitis C virus antiviral therapies.

Disease-modifying anti-rheumatic drugs are a major contributor to specialty drug spending.

The American College of Rheumatology said a recent Medicare rule may affect prescription drug access.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, talks about why the Certified Specialty Pharmacist distinction is significant.

EB-101 is the only gene therapy that has received this designation for Epidermolysis Bullosa.

Top news of the day from across the health care landscape.

Identifying and overcoming resistance to the use of generic HIV medications is becoming increasingly important to lower drug costs.

The FDA updated the labeling for rilipivirine (Edurant) for the treatment of HIV-positive pregnant patients who were on stable treatment prior to conception and who are virologically suppressed.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, tackles some of the challenges in starting a new specialty pharmacy.

New Amazon health care venture may lead to more effective specialty drug management.